Abstract:Background: PB-201, a partial, pancreas/liver-dual glucokinase activator, showed good tolerance and glycaemic effects in multinational studies. We aimed to determine its optimal dose and to evaluate its safety, pharmacokinetics, and pharmacodynamics in Chinese patients with type 2 diabetes. Methods: In this double-blind, randomised, four-period, crossover, phase 1 trial in China (NCT03973515), adult patients with drug-naive type 2 diabetes were randomised (1:1:1:1) to four sequence groups using a computer-generated randomisation table. In each period, they received oral placebo or PB-201 (50+50, 100+50, or 100+100 mg split doses) for 7 days. Investigators and patients were masked to treatment assignment. The primary endpoints were safety and pharmacokinetics. Continuous glucose monitoring was used to delineate the glucose excursion profile.Findings: Between July 18, 2019 and September 05, 2019, 16 patients were randomised. PB-201 showed a dose-proportional pharmacokinetic profile and dose-dependent lowering of blood glucose, similar to findings in non-Chinese populations. PB-201 at 100+50 and 100+100 mg increased mean time in range (49·210% [standard deviation 27], 56·130% [25], and 63·330% [20] with three doses, respectively) versus placebo (49·380% [27]) and reduced estimated glycated haemoglobin from baseline (−0·5445% [1·654], −1·063% [1·236], and −1·888% [1·381] vs −0·581% [1·200]). All treatment-emergent adverse events were mild. No patients had hypoglycaemia with venous/capillary glucose <3·9 mmol/L or nocturnal hypoglycaemia.Interpretation: PB-201 100 mg twice daily is identified as the optimal dose, which shows promising glucose-lowering effects and low risks of hypoglycaemia and other side effects. Further investigation of PB-201 100 mg twice daily in confirmatory trials is warranted.Trial Registration: This trial was registered with ClinicalTrials.gov, number NCT03973515.Funding: PegBio.Declaration of Interest: YD and MX are employees of PegBio, and HZ is an ex-employee of PegBio. LJ has received fees for lecture presentations from AstraZeneca, Merck, Novartis, Lilly, Roche, Sanofi-Aventis and Takeda; consulting fees from AstraZeneca, Merck, Novartis, Lilly, Roche, Sanofi-Aventis and Takeda; and grants/research support from AstraZeneca, Bristol-Myers Squibb, Merck, Novartis and Sanofi-Aventis. All other authors declare no competing interests.Ethical Approval: The study protocol and informed consent information were approved by the ethics committee at Peking University Third Hospital.

A Randomized Double-Blind Phase Ib Clinical Trial of SY-009 in Patients with Type 2 Diabetes Mellitus.

733-P: Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

A Double-Blind Randomized Multiple Center Clinical Trial on Observing the Effect of Fixed-Dose Glipizide/metformin on Type 2 Diabetes

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Glucokinase Activator PB-201 and Its Effects on the Glucose Excursion Profile in Drug-Naive Chinese Patients with Type 2 Diabetes: A Randomised Controlled, Crossover Trial

A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

Efficacy and Safety of DBPR108 Monotherapy in Patients with Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Glucokinase Activator PB-201 and Its Effects on the Glucose Excursion Profile in Drug-Naïve Chinese Patients with Type 2 Diabetes: a Randomised Controlled, Crossover, Single-Centre Phase 1 Trial

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin

239-OR: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Four-Period, Crossover Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Three Dose Levels of PB201 As Monotherapy in Subjects with Type 2 Diabetes Mellitus

770-P: Efficacy and Safety of Once-Weekly PB-119 Monotherapy Vs. Placebo in Chinese Patients with Type 2 Diabetes in a Randomized Controlled Trial

Henagliflozin Monotherapy In Patients With Type 2 Diabetes Inadequately Controlled On Diet And Exercise: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Efficacy and safety of henagliflozin combined with continuous subcutaneous insulin infusion in the treatment of Chinese inpatients with type 2 diabetes mellitus based on a continuous glucose monitoring system: protocol of a multicentre, open-label, inpatient, randomised, controlled trial

The Key Role of Shenyan Kangfu Tablets, a Chinese Patent Medicine for Diabetic Nephropathy: Study Protocol for a Randomized, Double-Blind and Placebo-Controlled Clinical Trial

763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study

Pharmacokinetics, Pharmacodynamics, and Tolerability of JY09 in Healthy Chinese Subjects: A Titrating, Dose-Escalating Study

[A Randomized, Double Blind, Placebo-Controlled, Parallel and Multicenter Study to Evaluate the Safety and Efficacy of Pioglitazone with Sulphonylurea in Type 2 Diabetic Patients].

Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and Multiple-Dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus

Phase III, Randomized, Double‐blind, Placebo‐controlled Study to Evaluate the Efficacy and Safety of Teneligliptin Monotherapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise

Effectiveness and safety of Daixie Decoction granules combined with metformin for the treatment of T2DM patients with obesity: study protocol for a randomized, double-blinded, placebo-controlled, multicentre clinical trial

[Efficacy and Safety of Alogliptin in Treatment of Type 2 Diabetes Mellitus: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial in Mainland China].